[HTML][HTML] Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer
VD de Jager, W Timens, A Bayle, J Botling… - The Lancet Regional …, 2024 - thelancet.com
For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies
have changed significantly due to the introduction of targeted therapies and immunotherapy …
have changed significantly due to the introduction of targeted therapies and immunotherapy …
[HTML][HTML] RELAY, ramucirumab plus erlotinib (RAM+ ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+ NSCLC): association between TP53 status and …
M Nishio, L Paz-Ares, M Reck, K Nakagawa… - Clinical Lung Cancer, 2023 - Elsevier
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) in RELAY, a randomised Phase 3 trial in patients with untreated …
free survival (PFS) in RELAY, a randomised Phase 3 trial in patients with untreated …
[HTML][HTML] Overall survival benefits of first-line treatments for Asian patients with advanced EGFR-mutated NSCLC harboring L858R mutation: a systematic review and …
SK Chan, HCW Choi, VHF Lee - JTO Clinical and Research Reports, 2022 - Elsevier
Introduction Randomized controlled trials have investigated different first-line treatments for
patients with advanced EGFR-mutated NSCLC. Nevertheless, their efficacy, in particular, the …
patients with advanced EGFR-mutated NSCLC. Nevertheless, their efficacy, in particular, the …
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung …
H Kawachi, T Yamada, A Yoshimura… - … in medical oncology, 2023 - journals.sagepub.com
Background: Osimertinib is a standard treatment option for epidermal growth factor receptor
(EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, osimertinib …
(EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, osimertinib …
[HTML][HTML] Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
T Masuda, S Miura, Y Sato, M Tachihara, A Bessho… - Scientific Reports, 2023 - nature.com
Small amounts of epidermal growth factor receptor (EGFR) T790M mutation (micro-T790M),
which is detected using droplet digital PCR (ddPCR) but not conventional PCR, in formalin …
which is detected using droplet digital PCR (ddPCR) but not conventional PCR, in formalin …
The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer
R Lasala, A Romagnoli, F Santoleri, V Isgrò… - European Journal of …, 2024 - Springer
Methods Taking into account the National Comprehensive Cancer Network (NCCN)
guidelines updated to 2022, which list all available treatments for each NSCLC subtype, the …
guidelines updated to 2022, which list all available treatments for each NSCLC subtype, the …
[HTML][HTML] The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR …
D Rocco, L Della Gravara, G Palazzolo… - Cancer Drug …, 2022 - ncbi.nlm.nih.gov
As of today, only two antiangiogenic monoclonal antibodies plus epidermal growth factor
receptor-tyrosine kinase inhibitor (EGFR-TKI) combinations are FDA and EMA-approved …
receptor-tyrosine kinase inhibitor (EGFR-TKI) combinations are FDA and EMA-approved …
[HTML][HTML] Highly Selective, Single-Tube Colorimetric Assay for Detection of Multiple Mutations in the Epidermal Growth Factor Receptor Gene
J Wang, T Pan, S Zhang - The Journal of Molecular Diagnostics, 2023 - Elsevier
Many closed-tube methods are designed to detect DNA biomarkers. However, the utility of
biomarkers such as a DNA mutation related to personalized medicine is limited as the …
biomarkers such as a DNA mutation related to personalized medicine is limited as the …
[HTML][HTML] 抗血管生成药物联合EGFR-TKI 治疗EGFR 突变晚期非小细胞肺癌的研究进展
李博文， 薛剑超， 王亚东， 黄志诚， 梁乃新… - Chinese Journal of …, 2022 - ncbi.nlm.nih.gov
肺癌是最常见、 致死率最高的肿瘤性疾病之一， 使用表皮生长因子受体酪氨酸激酶抑制剂（
epidermal growth factor receptor tyrosine kinase inhibitor, EGRF-TKI） 已经成为EGFR …
epidermal growth factor receptor tyrosine kinase inhibitor, EGRF-TKI） 已经成为EGFR …
Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated Advanced Non-small Cell Lung Cancer
LI Bowen, XUE Jianchao, W Yadong… - Zhongguo Fei Ai …, 2022 - search.proquest.com
肺癌是最常见, 致死率最高的肿瘤性疾病之一, 使用表皮生长因子受体酪氨酸激酶抑制剂
(epidermal growth factor receptor tyrosine kinase inhibitor, EGRF-TKI) 已经成为 EGFR …
(epidermal growth factor receptor tyrosine kinase inhibitor, EGRF-TKI) 已经成为 EGFR …